Differences in platelet size according to the type of treatment in myeloproliferative neoplasms: their effect on proplatelet morphology

CELLUCI MS.; MARIN OYARZUN CP.; GLEMBOTSKY AC.; GOETTE NP.; GRODZIELSKI M.; BARONI PIETTO CM.; HELLER PG.; MARTA RF.

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencia y LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica.; 2019

Previously we demonstrated an increase in maximum platelet diameter in patients with Myeloproliferative neoplasms (MPN) treated with anagrelide (ANA), α-interferon (αIFN), or ruxolitinib (Ruxo), while decreased in patients treated with hydroxyurea (HU). Here, we extended the study to 75 MPN patients. The study was approved by the Ethical Committee and patients, controls and mothers from whom umbilical cord blood was obtained, signed the informed consent. Platelets were larger in CalR+ than JAK2+ patients, both in untreated and HU treated patients, although statistical differences were reached only in the latter group (Mann Whitney test p